APOBEC3A and lung carcinoma: In addition, CRISPR-mediated deletion of APOBEC3A significantly reduced double-strand DNA breaks and delayed the emergence of drug resistance, indicating APOBEC3A as a potential target for preventing or delaying acquired resistance in lung cancer therapy20.